FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146982160> ?p ?o ?g. }

• W2146982160 endingPage "4399" @default.
• W2146982160 startingPage "4390" @default.
• W2146982160 abstract "Abstract Purpose: We initially observed that the presence of circulating NY-ESO-1– and/or Melan-A–specific T cells in patients with stage IV melanoma was significantly associated with prolonged survival. Here, we report the ways in which the phenotypes and functions of these T cells differentially affect survival in patients preselected for NY-ESO-1 and/or Melan-A reactivity. Experimental Design: We assayed functional antigen-reactive T cells recognizing NY-ESO-1 and/or Melan-A after in vitro stimulation using overlapping peptide pools. After restimulation, we assayed six cytokines simultaneously by intracellular cytokine staining. This allowed us to analyze the functional antigen response of both CD4+ and CD8+ T cells at the single-cell level. Results: We observed that NY-ESO-1 stimulated mainly CD4+ T cells, whereas Melan-A more often stimulated CD8+ T cells. NY-ESO-1 reactivity was not associated with an additional impact on survival, whether CD4+ T cells, CD8+ T cells, or both types of T cells were responding. In contrast, recognition of Melan-A by CD4+ T cells was associated with reduced survival in our cohort of patients preselected for NY-ESO-1 and/or Melan-A reactivity (that is, in patients with exceptionally long survival). We further observed a negative effect on survival in patients with CD4+ T cells producing IL4 and IL17 upon Melan-A stimulation. Their prognosis was comparable to patients without any Melan-A reactivity. Conclusions: The nature and prognostic impact of specific T-cell responses is different according to targeted antigen. Independent from phenotype and functional aspects, NY-ESO-1 reactivity is associated with good prognosis. In terms of Melan-A, antigen-specific CD8+ but not CD4+ responses are associated with prolonged survival. Clin Cancer Res; 20(16); 4390–9. ©2014 AACR." @default.
• W2146982160 created "2016-06-24" @default.
• W2146982160 creator A5001548963 @default.
• W2146982160 creator A5002652120 @default.
• W2146982160 creator A5004497401 @default.
• W2146982160 creator A5015203206 @default.
• W2146982160 creator A5018536695 @default.
• W2146982160 creator A5027331206 @default.
• W2146982160 creator A5034365278 @default.
• W2146982160 creator A5035000626 @default.
• W2146982160 creator A5044487752 @default.
• W2146982160 creator A5049279715 @default.
• W2146982160 creator A5053563008 @default.
• W2146982160 creator A5054219763 @default.
• W2146982160 creator A5056227404 @default.
• W2146982160 creator A5057881366 @default.
• W2146982160 creator A5063812788 @default.
• W2146982160 creator A5066075003 @default.
• W2146982160 creator A5088707945 @default.
• W2146982160 date "2014-08-13" @default.
• W2146982160 modified "2023-10-11" @default.
• W2146982160 title "Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma" @default.
• W2146982160 cites W1570475337 @default.
• W2146982160 cites W1892164682 @default.
• W2146982160 cites W1995570137 @default.
• W2146982160 cites W2006428939 @default.
• W2146982160 cites W2010641182 @default.
• W2146982160 cites W2014206073 @default.
• W2146982160 cites W2026707626 @default.
• W2146982160 cites W2027940608 @default.
• W2146982160 cites W2039769611 @default.
• W2146982160 cites W2049504854 @default.
• W2146982160 cites W2053737219 @default.
• W2146982160 cites W2077204887 @default.
• W2146982160 cites W2100745065 @default.
• W2146982160 cites W2103675014 @default.
• W2146982160 cites W2104525960 @default.
• W2146982160 cites W2111713512 @default.
• W2146982160 cites W2116378201 @default.
• W2146982160 cites W2118982164 @default.
• W2146982160 cites W2128564429 @default.
• W2146982160 cites W2131365547 @default.
• W2146982160 cites W2137264143 @default.
• W2146982160 cites W2140683554 @default.
• W2146982160 cites W2143163879 @default.
• W2146982160 cites W2146526400 @default.
• W2146982160 cites W2147770922 @default.
• W2146982160 cites W2148360952 @default.
• W2146982160 cites W2151592384 @default.
• W2146982160 cites W2151957163 @default.
• W2146982160 cites W2158495245 @default.
• W2146982160 cites W2160834915 @default.
• W2146982160 cites W2162646864 @default.
• W2146982160 cites W2164194457 @default.
• W2146982160 cites W2164658014 @default.
• W2146982160 doi "https://doi.org/10.1158/1078-0432.ccr-14-1015" @default.
• W2146982160 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24938524" @default.
• W2146982160 hasPublicationYear "2014" @default.
• W2146982160 type Work @default.
• W2146982160 sameAs 2146982160 @default.
• W2146982160 citedByCount "35" @default.
• W2146982160 countsByYear W21469821602014 @default.
• W2146982160 countsByYear W21469821602015 @default.
• W2146982160 countsByYear W21469821602016 @default.
• W2146982160 countsByYear W21469821602017 @default.
• W2146982160 countsByYear W21469821602018 @default.
• W2146982160 countsByYear W21469821602019 @default.
• W2146982160 countsByYear W21469821602020 @default.
• W2146982160 countsByYear W21469821602021 @default.
• W2146982160 countsByYear W21469821602022 @default.
• W2146982160 countsByYear W21469821602023 @default.
• W2146982160 crossrefType "journal-article" @default.
• W2146982160 hasAuthorship W2146982160A5001548963 @default.
• W2146982160 hasAuthorship W2146982160A5002652120 @default.
• W2146982160 hasAuthorship W2146982160A5004497401 @default.
• W2146982160 hasAuthorship W2146982160A5015203206 @default.
• W2146982160 hasAuthorship W2146982160A5018536695 @default.
• W2146982160 hasAuthorship W2146982160A5027331206 @default.
• W2146982160 hasAuthorship W2146982160A5034365278 @default.
• W2146982160 hasAuthorship W2146982160A5035000626 @default.
• W2146982160 hasAuthorship W2146982160A5044487752 @default.
• W2146982160 hasAuthorship W2146982160A5049279715 @default.
• W2146982160 hasAuthorship W2146982160A5053563008 @default.
• W2146982160 hasAuthorship W2146982160A5054219763 @default.
• W2146982160 hasAuthorship W2146982160A5056227404 @default.
• W2146982160 hasAuthorship W2146982160A5057881366 @default.
• W2146982160 hasAuthorship W2146982160A5063812788 @default.
• W2146982160 hasAuthorship W2146982160A5066075003 @default.
• W2146982160 hasAuthorship W2146982160A5088707945 @default.
• W2146982160 hasBestOaLocation W21469821601 @default.
• W2146982160 hasConcept C147483822 @default.
• W2146982160 hasConcept C154317977 @default.
• W2146982160 hasConcept C167672396 @default.
• W2146982160 hasConcept C202751555 @default.
• W2146982160 hasConcept C203014093 @default.
• W2146982160 hasConcept C2777658100 @default.
• W2146982160 hasConcept C2778690821 @default.
• W2146982160 hasConcept C502942594 @default.

• next